722 related articles for article (PubMed ID: 21945953)
1. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.
Louis E; Mary JY; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Dupas JL; Pillant H; Picon L; Veyrac M; Flamant M; Savoye G; Jian R; Devos M; Porcher R; Paintaud G; Piver E; Colombel JF; Lemann M;
Gastroenterology; 2012 Jan; 142(1):63-70.e5; quiz e31. PubMed ID: 21945953
[TBL] [Abstract][Full Text] [Related]
2. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
Hyams J; Crandall W; Kugathasan S; Griffiths A; Olson A; Johanns J; Liu G; Travers S; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano R;
Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
[TBL] [Abstract][Full Text] [Related]
3. Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study.
Chauvin A; Le Thuaut A; Belhassan M; Le Baleur Y; Mesli F; Bastuji-Garin S; Delchier JC; Amiot A
Dig Liver Dis; 2014 Aug; 46(8):695-700. PubMed ID: 24893686
[TBL] [Abstract][Full Text] [Related]
4. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
Maser EA; Villela R; Silverberg MS; Greenberg GR
Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
[TBL] [Abstract][Full Text] [Related]
5. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
[TBL] [Abstract][Full Text] [Related]
6. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA
Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724
[TBL] [Abstract][Full Text] [Related]
7. Risk Factors for Rescue Therapy in Crohn's Patients Maintained on Infliximab After Withdrawal of the Immunomodulator: A Long-Term Follow-Up.
Fischer M; Campbell SC; Calley CSJ; Helper DJ; Chiorean MV; Fadda HM
Dig Dis Sci; 2017 Nov; 62(11):3131-3137. PubMed ID: 28986660
[TBL] [Abstract][Full Text] [Related]
8. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.
Laharie D; Mesli S; El Hajbi F; Chabrun E; Chanteloup E; Capdepont M; Razaire S; de Lédinghen V; Zerbib F
Aliment Pharmacol Ther; 2011 Aug; 34(4):462-9. PubMed ID: 21671970
[TBL] [Abstract][Full Text] [Related]
9. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study.
Steenholdt C; Molazahi A; Ainsworth MA; Brynskov J; Østergaard Thomsen O; Seidelin JB
Scand J Gastroenterol; 2012 May; 47(5):518-27. PubMed ID: 22375898
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study.
Peyrin-Biroulet L; Laclotte C; Bigard MA
Aliment Pharmacol Ther; 2007 Mar; 25(6):675-80. PubMed ID: 17311600
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of Crohn's disease by infliximab. About 20 cases].
Serghini M; Karoui S; Meknini M; Matri S; Kallel L; Fekih M; Boubaker J; Filali A
Tunis Med; 2009 Sep; 87(9):579-82. PubMed ID: 20180377
[TBL] [Abstract][Full Text] [Related]
12. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study.
Seiderer J; Brand S; Dambacher J; Pfennig S; Jürgens M; Göke B; Ochsenkühn T
Aliment Pharmacol Ther; 2007 Apr; 25(7):787-96. PubMed ID: 17373917
[TBL] [Abstract][Full Text] [Related]
14. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.
Van Assche G; Magdelaine-Beuzelin C; D'Haens G; Baert F; Noman M; Vermeire S; Ternant D; Watier H; Paintaud G; Rutgeerts P
Gastroenterology; 2008 Jun; 134(7):1861-8. PubMed ID: 18440315
[TBL] [Abstract][Full Text] [Related]
15. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study.
Kallel L; Ayadi I; Matri S; Fekih M; Mahmoud NB; Feki M; Karoui S; Zouari B; Boubaker J; Kaabachi N; Filali A
Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):340-5. PubMed ID: 19581809
[TBL] [Abstract][Full Text] [Related]
16. Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy.
Molnár T; Lakatos PL; Farkas K; Nagy F; Szepes Z; Miheller P; Horváth G; Papp M; Palatka K; Nyári T; Bálint A; Lőrinczy K; Wittmann T
Aliment Pharmacol Ther; 2013 Jan; 37(2):225-33. PubMed ID: 23181359
[TBL] [Abstract][Full Text] [Related]
17. [Frequency and possible reasons for the loss of response to biological therapy in Crohn's disease after a one-year treatment period].
Molnár T; Farkas K; Nyári T; Szepes Z; Nagy F; Kiss T; Wittmann T
Orv Hetil; 2011 Jun; 152(24):951-7. PubMed ID: 21609921
[TBL] [Abstract][Full Text] [Related]
18. Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease.
Sinitsky DM; Lemberg DA; Leach ST; Bohane TD; Jackson R; Day AS
J Gastroenterol Hepatol; 2010 Apr; 25(4):810-6. PubMed ID: 20492339
[TBL] [Abstract][Full Text] [Related]
19. Timing infliximab therapy in pediatric Crohn's disease.
Kirschner BS; Huo D
Gastroenterology; 2007 Mar; 132(3):1167-70. PubMed ID: 17383435
[No Abstract] [Full Text] [Related]
20. [Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab): results of a multicentric and retrospective study].
Doubremelle M; Bourreille A; Zerbib F; Heresbach D; Metman EH; Beau P; Gournay J; Galmiche JP
Gastroenterol Clin Biol; 2002 Nov; 26(11):973-9. PubMed ID: 12483127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]